Who owns VYNE THERAPEUTICS INC?
- Ticker: VYNE
- CUSIP Number: 92941v308
Tip: Access positions for across all investors
Analyze quarterly positions in Vyne Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Vyne Therapeutics stock
Who bought or sold VYNE THERAPEUTICS INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| None | 1.6M | $942k | 100% | Dec 2025 |
|
| Frigate Ventures | 1.3M | $739k | 100% | Dec 2025 |
|
| Nantahala Capital Management | 1.0M | $580k | 100% | Dec 2025 |
|
| Baker Bros. Advisors | 851k | $285k | 100% | Sep 2025 |
|
| Acadian Asset Management | 639k | $370k | 43% | Dec 2025 |
|
| KVP Capital Advisors | 501k | $290k | 100% | Dec 2025 |
|
| Vanguard Group | 315k | $182k | 65% | Dec 2025 |
|
| Ikarian Capital | 265k | $154k | -9% | Dec 2025 |
|
| ADAR1 Capital Management | 254k | $147k | 100% | Dec 2025 |
|
| Geode Capital Management | 225k | $131k | 64% | Dec 2025 |
|
| Two Sigma Investments | 221k | $74k | 100% | Sep 2025 |
|
| Susquehanna International | 100k | $58k | 74% | Dec 2025 |
|
| Rangeley Capital | 100k | $58k | 100% | Dec 2025 |
|
| Boothbay Fund Management | 81k | $47k | -24% | Dec 2025 |
|
| XTX Topco | 79k | $46k | 100% | Dec 2025 |
|
| Bridgeway Capital Management | 77k | $26k | 0% | Sep 2025 |
|
| Jane Street | 72k | $45k | -51% | Dec 2025 |
|
| UBS Group | 63k | $36k | 1026% | Dec 2025 |
|
| Two Sigma Advisers | 57k | $19k | 100% | Sep 2025 |
|
| GSA Capital Partners | 54k | $31k | 50% | Dec 2025 |
|
| Corsair Capital Management | 50k | $17k | 400% | Sep 2025 |
|
| BlackRock | 44k | $26k | 0% | Dec 2025 |
|
| Virtu Financial | 25k | $15k | 100% | Dec 2025 |
|
| FNY Investment Advisers | 25k | $14k | 100% | Dec 2025 |
|
| Northern Trust | 23k | $13k | 0% | Dec 2025 |
|
| Commonwealth Equity Services | 18k | $11k | 0% | Dec 2025 |
|
| State Street Corporation | 16k | $9.1k | 0% | Dec 2025 |
|
| Harvest Investment Services | 11k | $6.4k | 0% | Dec 2025 |
|
| Tower Research Capital | 3.6k | $2.1k | -1% | Dec 2025 |
|
| Royal Bank of Canada | 2.4k | $999.912000 | 0% | Sep 2025 |
|
| Acorn Capital Advisors | 1.4k | $827.070000 | -100% | Dec 2025 |
|
| Mb, Levis & Associates | 1.0k | $603.988200 | 0% | Dec 2025 |
|
| Northwestern Mutual Wealth Management Company | 800.00 | $464.000000 | 100% | Dec 2025 |
|
| Hurley Capital | 561.00 | $325k | 100% | Dec 2025 |
|
| CWM | 500.00 | $0 | 0% | Dec 2025 |
|
| Centerpoint Advisors | 350.00 | $0 | 0% | Dec 2025 |
|
| Jpmorgan Chase & Co | 146.00 | $48.661800 | 100% | Sep 2025 |
|
| Wells Fargo & Company | 65.00 | $37.999000 | 0% | Dec 2025 |
|
| Truvestments Capital | 25.00 | $15.000000 | 0% | Dec 2025 |
|
| Newbridge Financial Services Group | 10.00 | $6.000000 | 0% | Dec 2025 |
|
Who sold out of Vyne Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Citadel Advisors | Jun 2025 | 1.0M | $1.7M |
| Adage Capital Partners GP | Jun 2025 | 644k | $1.1M |
| Shay Capital | Sep 2025 | 493k | $165k |
| Palo Alto Investors | Jun 2025 | 445k | $735k |
| Springbok Capital Management | Jun 2025 | 65k | $107k |